Dyax has several products in various stages of clinical development.
Our therapeutic product candidates include fully human monoclonal antibodies as well as small proteins and peptides. Dyax is particularly focused on medical advances in the areas of oncology and inflammation. Our discovery technology, phage display, provides us with the advantage of being able to both identify and then develop our own clinical leads for our internal pipeline.
Internal Pipeline
*One Phase 3 trial completed and a second one, known as EDEMA4, in progress.
|
